metaEvidence

	atezolizumab based treatment	avelumab based treatment	dostarlimab based treatment	durvalumab based treatment		pembrolizumab based treatment
	atezolizumab plus SoC	avelumab plus SoC	dostarlimab plus soC	durvalumab plus olaparib plus SoC	durvalumab plus SoC	pembrolizumab plus lenvatinib	pembrolizumab plus SoC

Comparator: vs placebo plus SoC; vs Standard of Care (SoC);
Risk of bias: low; some concerns; high; NA;